Aandelen in “Farmaceutische Producten: Generisch”

Aandeel Datum Koers Evolutie
vlag Dr. Reddy's Labs 21/08 12,180 USD
+0,58% 		+0,58%

Nieuws over “Farmaceutische Producten: Generisch”

19/08 · U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome · Persbericht

19/08 · U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome · Persbericht

11/08 · Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy · Persbericht

31/07 · Dr. Reddy's Laboratories (RDY) Securities Investigation Notice - Levi & Korsinsky · Persbericht

29/07 · Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy · Persbericht

27/07 · RDY SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Dr. Reddy's Laboratories · Persbericht

24/07 · Dr. Reddy's Laboratories Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Dr. Reddy's Laboratories (RDY) · Persbericht

24/07 · Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit · Persbericht

16/07 · SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of July 27, 2026 in Zoetis Inc. Lawsuit - ZTS · Persbericht

15/07 · Zoetis Inc. (ZTS) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit - Contact KTMC · Persbericht

15/07 · Levi & Korsinsky Reminds Zoetis Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of July 27, 2026 - ZTS · Persbericht

10/07 · Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit · Persbericht

9/07 · Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis · Persbericht

7/07 · Zoetis Inc. (ZTS) Class Action Lawsuit Seeks Recovery for Investors; July 27, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP · Persbericht

7/07 · Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results · Persbericht

1/07 · Zoetis Inc. (ZTS) Investors: July 27, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP · Persbericht

26/06 · Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit · Persbericht

25/06 · Zoetis Inc. (ZTS) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit - Contact Kessler Topaz Meltzer & Check, LLP · Persbericht

24/06 · Lost Money on Zoetis Inc. (ZTS)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky · Persbericht

19/06 · Zoetis Inc. (ZTS) Class Action Lawsuit: Investors July 27 2026, Deadline - Contact KTMC · Persbericht

18/06 · ZTS INVESTOR NOTICE: Zoetis Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit · Persbericht

Mijn selecties